




**Patent Office
Canberra**

I, JONNE YABSLEY, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. 2002953604 for a patent by FUJISAWA PHARMACEUTICAL CO. and LTD. as filed on 30 December 2002.



WITNESS my hand this
Thirtieth day of May 2003

A handwritten signature in cursive script, reading "J R Yabsley".

JONNE YABSLEY
TEAM LEADER EXAMINATION
SUPPORT AND SALES

Fujisawa Pharmaceutical Co., Ltd.

A U S T R A L I A

Patents Act 1990

PROVISIONAL SPECIFICATION

for the invention entitled:

"Aminoalcohol Derivatives"

The invention is described in the following statement:

DESCRIPTION

AMINOALCOHOL DERIVATIVES

5 FIELD OF THE INVENTION

This invention relates to new aminoalcohol derivatives and salts thereof which are beta-3 (β_3) adrenergic receptor agonists and useful as a medicament.

10 BACKGROUND OF THE INVENTION

International Publication No. WO 90/06299, published June 14, 1990, describes derivatives of phenylethanalamines as having an effect on the metabolism, preferably reduction of the blood sugar level and body fat.

15

DISCLOSURE OF THE INVENTION

This invention relates to new aminoalcohol derivatives which are β_3 adrenergic receptor agonists and salts thereof.

More particularly, it relates to new aminoalcohol
20 derivatives and salts thereof which have gut sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence, anti-pollakiuria activities, anti-diabetes and anti-obesity, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a
25 method of using the same therapeutically in the treatment and/or prevention of gastro-intestinal disorders caused by smooth muscle contractions in a human being or an animal.


One object of this invention is to provide new and useful aminoalcohol derivatives and salts thereof which have
30 gut sympathomimetic, anti-ulcerous, lipolytic, anti-urinary incontinence, anti-pollakiuria activities, anti-diabetes and anti-obesity.

Another object of this invention is to provide processes for the preparation of said aminoalcohol
35 derivatives and salts thereof.



A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said aminoalcohol derivatives and salts thereof.

Still further object of this invention is to provide a
5 therapeutic method for the treatment and/or prevention of aforesaid diseases in a human being or an animal, using said aminoalcohol derivatives and salts thereof.

The object aminoalcohol derivatives of this invention
10 are new and can be represented by compound of the following formula [I]:



wherein




25 X is bond, -O-, -OCH₂-, -S- or $\begin{array}{c} \text{N-} \\ | \\ \text{R}^7 \end{array}$ (in which R⁷ is

hydrogen or lower alkyl),

Y is bond, -O-(CH₂)_n- (in which n is 1, 2, 3 or 4),

-(CH₂)_m- (in which m is 1, 2, 3 or 4),





R¹ is hydrogen or halogen,


R² is hydrogen or an amino protective group,

35 R³ is hydrogen or lower alkyl,

R^4 is hydrogen or lower alkyl,
 R^5 and R^8 are each independently hydrogen, halogen, hydroxy,
 lower alkyl, lower alkoxy, cyclo(lower)alkyloxy, amino,
 mono(or di)(lower)alkylamino, mono(or di or
 tri)halo(lower)alkyl, cyano or phenyl,
 R^6 is hydrogen or lower alkyl, and
 i is 1 or 2,

provided that when X is bond,  is  and

10




then R^5 is not hydrogen,
 or a salt thereof.

According to this invention, the object compounds can
 be prepared by processes which are illustrated in the
 following schemes.


Process 1

20




or a salt thereof

30




or a salt thereof

35


Process 2

10


elimination reaction
of the amino protective
group



15





Process 3

25



30

35

Process 4Process 5

35 wherein A , B , X , Y , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^8 and i are each as defined above,

R_a^2 is an amino protective group, and
 X_1 and X_2 are each a leaving group.

As to the starting compounds [II], [III], [Ia], [IV],
5 [V], [VI] and [VII], some of them are novel and can be
prepared by the procedures described in the Preparations and
Examples mentioned below or a conventional manner.

In the above and subsequent description of the present
10 specification, suitable examples of the various definition
to be included within the scope of the invention are
explained in detail in the following.

The term "lower" is intended to mean a group having 1
15 to 6, preferably 1 to 4, carbon atom(s), unless otherwise
indicated.

Suitable "lower alkyl" and "lower alkyl" moiety in the
terms of "mono(or di)(lower)alkylamino" and "mono(or di or
20 tri)halo(lower)alkyl" may include straight or branched one
having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
1-methylpentyl, tert-pentyl, neo-pentyl, hexyl, isohexyl and
the like.

25

Suitable "lower alkoxy" may include methoxy, ethoxy,
propoxy, isopropoxy, butoxy, iso-butoxy, tert-butoxy,
pentyloxy, tert-pentyloxy, hexyloxy and the like, in which
preferable one is methoxy or ethoxy.

30

Suitable "cyclo(lower)alkyl" moiety in the term of
"cyclo(lower)alkyloxy" may include cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl and the like, in which preferable
one is cyclohexyl.

35

Suitable "halogen" may be fluoro, chloro, bromo and iodo, in which preferable one is chloro.

Suitable "mono(or di or tri)halo(lower)alkyl" may
5 include chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1 or 2-chloroethyl, 1 or 2-bromoethyl, 1 or 2-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl and the like.

10

Suitable "leaving group" may include hydroxy, reactive group derived from hydroxy and the like.

Suitable "reactive group derived from hydroxy" may include acid residue and the like.

15

Suitable "acid residue" may include halogen (e.g. fluoro, chloro, bromo, iodo), acyloxy (e.g. acetoxy, tosyloxy, mesyloxy, trifluoromethanesulfonyloxy, etc.) and the like.

20

Suitable example of "amino protective group" moiety may be common amino protective group such as substituted or unsubstituted lower alkanoyl [e.g. formyl, acetyl, propionyl, trifluoroacetyl, etc.], phthaloyl, lower alkoxy carbonyl [e.g. tert-butoxycarbonyl, tert-amyloxycarbonyl, etc.],

25

substituted or unsubstituted aralkyloxycarbonyl [e.g. benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.], substituted or unsubstituted arenesulfonyl [e.g. benzenesulfonyl, tosyl, etc.], nitrophenylsulfenyl, ar(lower)alkyl [e.g. trityl, benzyl, etc.], and the like, in

30

which preferable one is tert-butoxycarbonyl.

Suitable salts of the object aminoalcohol derivative [I] are pharmaceutically acceptable salts and include conventional non-toxic salts such as an inorganic acid
35 addition salt [e.g. hydrochloride, hydrobromide, sulfate,

phosphate, etc.), an organic acid addition salt [e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartrate, citrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc., an alkali metal
5 salt [e.g. sodium salt, potassium salt, etc.] or the like.

The Processes 1 to 5 for preparing the object compounds of the present invention are explained in detail in the following.

10

Process 1

The object compound [I] or a salt thereof can be prepared by reacting a compound [II] with a compound [III] or a salt thereof.

15

Suitable salt of the compound [III] may be the same as those exemplified for the compound [I].

The reaction is preferably carried out in the presence of a base such as an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkaline earth
20 metal carbonate [e.g. magnesium carbonate, calcium carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], tri(lower)alkylamine [e.g. trimethylamine, triethylamine, etc.], picoline or the like.

The reaction is usually carried out in a conventional
25 solvent, such as an alcohol [e.g. methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not adversely influence the reaction.

The reaction temperature is not critical, and the
30 reaction can be carried out under cooling to heating.

Process 2

The object compound [Ib] or a salt thereof can be prepared by subjecting a compound [Ia] or a salt thereof to
35 elimination reaction of the amino protective group.

Suitable salts of the compounds [Ia] and [Ib] may be the same as those exemplified for the compound [I].

This reaction can be carried out in a similar manner to that of Example 11 mentioned below.

5

Process 3

The object compound [Ic] or a salt thereof can be prepared by reacting a compound [IV] or a salt thereof with a compound [V] or a salt thereof.

10 Suitable salts of the compounds [Ic], [IV] and [V] may be the same as those exemplified for the compound [I].

This reaction can be carried out in a similar manner to that of Example 15 mentioned below.

15 Process 4

The object compound [Ic] or a salt thereof can be prepared by reacting a compound [IV] or a salt thereof with a compound [VI] or a salt thereof.

20 Suitable salts of the compound [Ic], [IV] and [VI] may be the same as those exemplified for the compound [I].

This reaction can be carried out in a similar manner to that of Example 9 mentioned below.

Process 5

25 The object compound [Id] or a salt thereof can be prepared by reacting a compound [VII] or a salt thereof with a compound [V] or a salt thereof.

Suitable salts of the compounds [Id], [VII] and [V] may be the same as those exemplified for the compound [I].

30 This reaction can be carried out in a similar manner to that of Example 7 mentioned below.

The compounds obtained by the above processes can be isolated and purified by a conventional method such as
35 pulverization, recrystallization, column chromatography,

reprecipitation, or the like, and converted to the desired salt in conventional manners, if necessary.

It is to be noted that the compound [I] and the other compounds may include one or more stereoisomers due to
5 asymmetric carbon atoms, and all of such isomers and mixture thereof are included within the scope of this invention.

It is further to be noted that isomerization or rearrangement of the object compound [I] may occur due to the effect of the light, acid base or the like, and the
10 compound obtained as the result of said isomerization or rearrangement if also included within the scope of the present invention.

It is also to be noted that the solvating form of the compound [I] (e.g. hydrate, etc.) and any form of the
15 crystal of the compound [I] are included within the scope of the present invention.

The object compound [I] or a salt thereof possesses gut sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic,
20 anti-urinary incontinence and anti-pollakiuria activities, and are useful for the treatment and/or prevention of gastro-intestinal disorders caused by smooth muscle contractions in human beings or animals, and more particularly for the treatment and/or prevention of spasm or
25 hyperanakinesia in case of irritable bowel syndrome, gastritis, gastric ulcer, duodenal ulcer, enteritis, cholecystopathy, cholangitis, urinary calculus and the like; for the treatment and/or prevention of ulcer such as gastric ulcer, duodenal ulcer, peptic ulcer, ulcer causes by non
30 steroidal anti-inflammatory drugs, or the like; for the treatment and/or prevention of dysuria such as pollakiuria, urinary incontinence or the like in case of nervous pollakiuria, neurogenic bladder dysfunction, nocturia, unstable bladder, cystospasm, chronic cystitis, chronic
35 prostatitis, prostatic hypertrophy or the like; for the

treatment and/or prevention of pancreatitis, obesity, diabetes, glycosuria, hyperlipidemia, hypertension, atherosclerosis, glaucoma, melancholia, depression or the like; for the treatment and/or prevention of diseases as the
5 result of insulin resistance (e.g. hypertension, hyperinsulinemia, etc.); for the treatment and/or prevention of neurogenetic inflammation; and for reducing a wasting condition, and the like.

Additionally, β_3 adrenergic receptor agonists are known
10 to lower triglyceride and cholesterol levels and to raise high density lipoprotein levels in mammals (US Patent No. 5,451,677). Accordingly, the object compound [I] is useful in the treatment and/or prevention of conditions such as hyper-triglyceridaemia, hypercholesterolaemia and in
15 lowering high density lipoprotein levels as well as in the treatment of atherosclerotic and cardiovascular diseases and relates conditions.

Moreover, the object compound [I] is useful for
20 inhibiting uterine contractions, preventing premature labor, and treating and preventing dysmenorrhea.

In order to show the usefulness of the compound [I] for the prophylactic and therapeutic treatment of above-
25 mentioned disease in human being or animals, a representative compound of the compound [I] was tested on the following pharmaceutical test.

Test


30 Effect on the increase in intravesical pressure induced by carbachol in anesthetized dog

Test Method and Test Result

Female Beagle dogs weighing 8.0-15.0 kg were fasted for
35 24 hours and maintained under halothane anesthesia. A 12F

Foley catheter was lubricated with water soluble jelly, inserted into the urethral orifice and advanced approximately 10 cm until the balloon tip was placed well inside the bladder. The balloon was then inflated with 5 ml of room air and catheter slowly withdrawn just part the first resistance that is felt at the bladder neck. Urine was completely drained out through the catheter, and 30 ml of biological saline was infused. The catheter was connected to pressure transducer, and intravesical pressure was continuously recorder. Intravenous administration of the test compound inhibited carbachol (1.8 $\mu\text{l/kg}$)-induced increase in intravesical pressure (IVP).


Preferred embodiments of the object compound [I] are as follows:



X is bond, -O-, -OCH₂-, -S- or -N-
 $\begin{array}{c} | \\ \text{R}^7 \end{array}$ (in which R⁷ is

hydrogen or lower alkyl (more preferably C₁-C₄, most preferably methyl)),

Y is bond, -O-(CH₂)_n- (in which n is 1, 2, 3 or 4), -(CH₂)_m- (in which m is 1, 2, 3 or 4),



R¹ is hydrogen or halogen (more preferably chloro),

R² is hydrogen,

R³ is hydrogen or lower alkyl,

R⁴ is hydrogen,


R^5 is hydrogen, halogen (more preferably chloro), hydroxy,
lower alkyl (more preferably C_1 - C_4 , most preferably
methyl), lower alkoxy (more preferably C_1 - C_4 alkoxy,
5 most preferably methoxy) or cyclo(lower)alkyloxy (more
preferably cyclo(C_3 - C_6)alkyloxy, most preferably
cyclohexyloxy),

R^6 is hydrogen,


R^8 is hydrogen or lower alkyl (more preferably C_1 - C_4 alkyl,
10 most preferably methyl), and
 i is 1 or 2.

More preferred embodiments of the object compound [I]
are as follows:

15



20



X is bond, $-O-$, $-OCH_2-$, $-S-$ or $-N-$ (in which R^7 is
 $\begin{array}{c} | \\ R^7 \end{array}$

hydrogen or lower alkyl (more preferably C_1 - C_4 , most
preferably methyl)),

25 Y is bond, $-O-(CH_2)_n-$ (in which n is 1 or 2) or $-(CH_2)_m-$ (in
which m is 1 or 2),

R^1 is hydrogen or halogen (more preferably chloro),

R^2 is hydrogen,

R^3 is hydrogen or lower alkyl,

30 R^4 is hydrogen,

R^5 is hydrogen, halogen (more preferably chloro), hydroxy,
lower alkyl (more preferably C_1 - C_4 , most preferably
methyl), or lower alkoxy (more preferably C_1 - C_6 alkoxy,
most preferably methoxy),

35 R^6 is hydrogen,

R⁸ is hydrogen, and
i is 1.

5

The following Preparations and Examples are given for the purpose of illustrating this invention.

Preparation 1

10 A solution of N-benzyl-2-(4-bromophenyl)ethanamine
 (13.5 g) in ethanol (270 ml) was added (2R)-2-(3-
 chlorophenyl)oxirane (8.63 g) and the solution was refluxed
 for 48 hours. After cooling to room temperature, the
 solvent was removed by evaporation and the residue was
15 chromatographed on silica gel (eluent: hexane/ethyl acetate
 = 9/1) to give (1R)-2-[benzyl[2-(4-bromophenyl)ethyl]amino]-
 1-(3-chlorophenyl)ethanol (18.6 g) as a colorless oil.

 NMR (CDCl₃, δ): 2.58 (1H, dd, J=10, 13Hz), 2.68-2.89
 (5H, m), 3.56 (1H, d, J=13Hz), 3.92 (1H, d,
20 J=13Hz), 4.59 (1H, dd, J=3.4, 10Hz), 6.97 (2H, d,
 J=8.3Hz), 7.21-7.40 (12H, m)
 (+)ESI-MS (m/z): 444 and 446 (MH⁺)

Preparation 2

25 To a solution of (1R)-2-[benzyl[2-(4-
 bromophenyl)ethyl]amino]-1-(3-chlorophenyl)ethanol (18.5 g)
 in N,N-dimethylformamide (40 ml) were successively added
 imidazole (3.96 g) and tert-butyldimethylsilyl chloride
 (7.52 g) and the solution was stirred at room temperature
30 for 14 hours. The reaction mixture was quenched by the
 addition of water (100 ml) and extracted with ethyl acetate
 (100 ml x 1). The extract was washed with water (100 ml x
 2), brine (100 ml x 1), and dried over magnesium sulfate.
 Filtration followed by evaporation gave a colorless oil,
35 which was chromatographed on silica gel (eluent:

hexane/ethyl acetate) to give (2R)-N-benzyl-N-[2-(4-bromophenyl)ethyl]-2-[[tert-butyl(dimethyl)silyl]oxy]-2-(3-chlorophenyl)ethanamine (21.0 g) as a colorless oil.

5 NMR (CDCl₃, δ): 0.15 (6H, s), 1.01 (9H, s), 2.72-2.82 (5H, m), 2.92 (1H, dd, J=5.9, 13Hz), 3.75 (1H, d, J=13.7Hz), 3.86 (1H, d, J=13.7Hz), 4.71 (1H, t-like, J=6.2Hz), 7.01 (2H, d, J=8.3Hz), 7.26-7.47 (9H, m), 7.48 (2H, d, J=8.3Hz)

(+)ESI-MS (m/z): 558 and 560 (MH⁺)

10

Preparation 3

To a solution of tert-butyl [2-(4-bromophenyl)ethyl][(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (500 mg) in 1,2-dimethoxyethane (6 ml) was added 5-formyl-2-thiopheneboronic acid (206 mg), tetrakis(triphenylphosphine)palladium (63 mg) and aqueous solution of sodium carbonate (2M, 1.0 ml), and the mixture was stirred at 80°C for 7 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-[4-(5-formyl-2-thienyl)phenyl]ethyl]carbamate (187 mg).

25

(+)ESI-MS (m/z): 508 (M+Na)⁺

Preparation 4

To a suspension of tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-(4-hydroxyphenyl)ethyl]carbamate (710 mg), 4-[[tert-butyl(dimethyl)silyl]oxy]phenylboronic acid (457 mg), triethylamine (1.26 ml) and powdered 4Å molecular sieves (700 mg) in dichloromethane (18 ml) was added copper(II) acetate (330 mg), and the mixture was stirred at room temperature for 18 hours under ambient atmosphere. The

35

resulting slurry was filtered off, and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give tert-butyl [2-[4-[4-[[tert-butyl(dimethyl)silyl]oxy]phenoxy]phenyl]ethyl][(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (600 mg).

(-)ESI-MS (m/z): 569 (M-H)⁻

Preparation 5

10 The following compounds were obtained according to a similar manner to that of Preparation 4.

(1) tert-Butyl [2-[4-[4-[[tert-butyl(dimethyl)silyl]oxy]phenyl]amino]phenyl]ethyl][(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate
15 (+)ESI-MS (m/z): 597 (M+H)⁺

(2) tert-Butyl [2-[4-[4-[[tert-butyl(dimethyl)silyl]oxy]phenyl](methyl)amino]phenyl]ethyl][(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate
20 (+)ESI-MS (m/z): 611 (M+H)⁺

Preparation 6

To a solution of tert-butyl [2-(4-aminophenyl)-ethyl][(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate
25 (1.75 g) and formaldehyde (37% w/w solution in water, 390 μ l) in 1,2-dichloroethane (20 ml) was added sodium triacetoxymethylborohydride (1.23 g), and the mixture was stirred at room temperature for 18 hours under nitrogen atmosphere.
30 The resulting mixture was poured into a mixture of 1N sodium hydroxide and chloroform, and the mixture was stirred for 20 minutes. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography
35 on silica gel (hexane/ethyl acetate = 2/1) to give tert-

butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-[4-(methylamino)phenyl]ethyl]carbamate (550 mg).

(+)ESI-MS (m/z): 405 (M+H)⁺

5 Preparation 7

To a suspension of 2-[4-[(4-methoxyphenyl)thio]phenyl]ethanamine (6.3 g) in methanol (45 ml) and tetrahydrofuran (10 ml) was added ethyl trifluoroacetate (2.89 ml), and the mixture was stirred at room temperature for 1 hour. The mixture was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give 2,2,2-trifluoro-N-[2-[4-[(4-methoxyphenyl)thio]phenyl]ethyl]acetamide (3.95 g).

(+)ESI-MS (m/z): 378 (M+Na)⁺

15

Preparation 8

Under nitrogen at 4°C, to a solution of 2,2,2-trifluoro-N-[2-[4-[(4-methoxyphenyl)thio]phenyl]ethyl]acetamide (1.5 g) in dichloromethane (15 ml) was added 1M boron tribromide in dichloromethane (10.5 ml), and the mixture was stirred at room temperature for 15 hours. The mixture was evaporated under reduced pressure. The residue was dissolved in a mixture of dichloromethane and saturated aqueous sodium bicarbonate. After separation, the organic layer was dried over magnesium sulfate and evaporated under reduced pressure to give 2,2,2-trifluoro-N-[2-[4-[(4-hydroxyphenyl)thio]phenyl]ethyl]acetamide (1.42 g).

(+)ESI-MS (m/z): 364 (M+Na)⁺

30 Preparation 9

To a solution of 2,2,2-trifluoro-N-[2-[4-[(4-hydroxyphenyl)thio]phenyl]ethyl]acetamide (480 mg) in methanol (5.0 ml) was added 1N sodium hydroxide solution (2.8 ml). The mixture was refluxed for 12 hours. The mixture was evaporated under reduced pressure. The residue

was dissolved in a mixture of dichloromethane (40 ml), 1N hydrochloric acid solution (2.0 ml) and water (15 ml).

After separation, the organic layer was dried over magnesium sulfate and evaporated under reduced pressure to give 4-[[4-

5 (2-aminoethyl)phenyl]thio]phenol (300 mg).

(-)ESI-MS (m/z): 244 (M-H)⁻

Preparation 10

4-[[4-(2-Aminoethyl)phenyl]thio]phenol (295 mg) and
10 (2R)-2-(3-chlorophenyl)oxirane (186 mg) in ethanol (3.5 ml) was refluxed for 6 hours. The mixture was evaporated. The residue was purified by column chromatography on silica gel (chloroform/methanol = 100/3) to give 4-[[4-[2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]thio]phenol
15 (155 mg).

(+)ESI-MS (m/z): 400 (M+H)⁺

The object compound above was protected at the imino group in a conventional manner to give tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-[4-[(4-hydroxyphenyl)-thio]phenyl]ethyl]carbamate (200 mg).

(+)ESI-MS (m/z): 500 (M+H)⁺

Preparation 11

25 The following compounds were obtained according to a similar manner to that of Preparation 10.

(1R)-2-[[2-(4-Bromophenyl)ethyl]amino]-1-(3-chlorophenyl)ethanol

30 (+)ESI-MS (m/z): 354 (M+H)⁺

tert-Butyl [2-(4-bromophenyl)ethyl][(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate

(+)ESI-MS (m/z): 454 (M+H)⁺

35

Example 1

To a solution of tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-[4-(5-formyl-2-thienyl)phenyl]ethyl]-carbamate (180 mg) in acetonitrile (2 ml) and pH 4 buffer solution (sodium dihydrogenphosphate) (1 ml) was added 30% hydrogen peroxide solution (30 μ l) and 80% sodium chlorite (67 mg) below 10°C. The reaction mixture was stirred at 50°C for 3 hours. The mixture was diluted with ethyl acetate, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure to give 5-[4-[2-[(tert-butoxycarbonyl) [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-2-thiophenecarboxylic acid (160 mg).

(-)ESI-MS (m/z): 500 (M-H)⁻

Example 2

The following compounds were obtained according to a similar manner to that of Example 4.

(1) 5-[4-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]-2-thiophenecarboxylic acid hydrochloride
NMR (DMSO-d₆, δ): 3.00-3.25 (6H, m), 4.95-4.99 (1H, m), 6.34 (1H, br), 7.33-7.47 (6H, m), 7.55 (1H, d, J=3.9Hz), 7.70-7.81 (3H, m), 9.05 (1H, br)
(-)ESI-MS (m/z): 400 (M-HCl-H)⁻

(2) [4-[[4-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]amino]phenoxy]acetic acid hydrochloride
NMR (DMSO-d₆, δ): 2.84-3.30 (6H, m), 4.39 (1H, br), 4.59 (2H, s), 4.97-5.03 (1H, m), 6.37 (1H, br), 6.80-7.07 (8H, m), 7.34-7.48 (4H, m), 8.85 (1H, br), 9.11 (1H, br)
(-)ESI-MS (m/z): 439 (M-HCl-H)⁻

(3) [4-[[4-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl](methylamino)phenoxy]acetic acid hydrochloride

5 NMR (DMSO-d₆, δ): 2.85-3.23 (6H, m), 3.17 (3H, s),
3.89-4.15 (1H, br), 4.65 (2H, s), 4.98-5.02 (1H, m), 6.68-7.08 (8H, m), 7.34-7.46 (4H, m), 8.86 (1H, br), 9.14 (1H, br)

(-)ESI-MS (m/z): 453 (M-HCl-H)⁻

10

(4) [4-[[4-[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl]thio]phenoxy]acetic acid hydrochloride

15 NMR (DMSO-d₆, δ): 2.94-3.33 (6H, m), 4.70 (2H, s),
4.97-5.01 (1H, m), 6.34 (1H, br), 6.96 (2H, d, J=8.7Hz), 7.02-7.23 (4H, m), 7.33-7.45 (6H, m), 8.97-9.18 (1H, br)

(-)ESI-MS (m/z): 456 (M-HCl-H)⁻

20 Example 3

To a solution of tert-butyl [2-[4-[4-[[tert-butyl(dimethyl)silyl]oxy]phenoxy]phenyl]ethyl][(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (370 mg) in tetrahydrofuran (4.0 ml) was added 1M tetrabutylammonium fluoride in tetrahydrofuran (1.2 ml), and the mixture was stirred at room temperature for 1 hour. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure to give a phenol product. To a solution of the product and potassium carbonate (94 mg) in N,N-dimethylformamide (4.0 ml) was added tert-butyl bromoacetate (133 mg), and the mixture was stirred at room temperature for 5 hours. The mixture was partitioned between ethyl acetate and water.

35 The organic layer was separated, washed with water and brine,

dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give tert-butyl [4-[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]phenoxy]-acetate (360 mg).

(-)ESI-MS (m/z): 597 (M-H)⁻

Example 4

10 A solution of tert-butyl [4-[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenoxy]phenoxy]acetate (305 mg) and 4N hydrochloride in 1,4-dioxane (5.0 ml) was stirred at room temperature for 24 hours. The resulting solid was collected
15 by filtration and dried to give [4-[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]phenoxy]-acetic acid hydrochloride (220 mg) as a white solid.

NMR (DMSO-d₆, δ): 2.95-3.33 (6H, m), 4.65 (2H, s),
4.99-5.04 (1H, m), 6.35 (1H, br), 6.83-7.00 (6H,
20 m), 7.23 (9H, d, J=8.5Hz), 7.39-7.47 (4H, m),
8.98-9.12 (1H, br)

(+)ESI-MS (m/z): 442 (M-HCl+H)⁺

Example 5

25 To a suspension of tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-(4-hydroxyphenyl)ethyl]carbamate (550 mg), (4-methoxycarbonylphenyl)boronic acid (300 mg), triethylamine (1.0 ml) and powdered 4Å molecular sieves (600 mg) in dichloromethane (8 ml) was added copper(II) acetate
30 (255 mg), and the mixture was stirred at room temperature for 18 hours under ambient atmosphere. The resulting slurry was filtered off, and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to
35 give methyl 4-[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-

chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]benzoate
(185 mg).

(+)ESI-MS (m/z): 526 (M+H)⁺

5 Example 6

To a solution of methyl 4-[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]benzoate (183 mg) in ethanol (1.2 ml) was added 1N aqueous sodium hydroxide
10 solution (0.6 ml), and the mixture was stirred at 40°C for 3 hours. The solvent was removed by evaporation, and the aqueous solution was acidified with 1N aqueous hydrochloride solution and extracted with ethyl acetate (30 ml x 2). The combined organic layers were washed with water and brine,
15 dried over magnesium sulfate and evaporated under reduced pressure to give a benzoic acid product. To a solution of the product in tetrahydrofuran (2.0 ml) was added 4N hydrochloride in 1,4-dioxane (1.0 ml), and the mixture was stirred at room temperature for 12 hours. The resulting
20 solid was collected by filtration and dried to give 4-[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-phenoxy]benzoic acid hydrochloride (127 mg).

NMR (DMSO-d₆, δ): 3.00-3.28 (6H, m), 4.99-5.04 (1H, m),
6.35 (1H, br), 6.97-7.12 (4H, m), 7.32-7.48 (6H,
25 m), 7.90-7.98 (2H, m), 9.03-9.35 (1H, br)

(-)ESI-MS (m/z): 410 (M-HCl-H)⁻

Example 7

To a solution of tert-butyl [2-(4-bromophenyl)ethyl]-
30 [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (400 mg) in 1,2-dimethoxyethane (6 ml) was added (4-methoxycarbonyl-2-methylphenyl)boronic acid (171 mg), tetrakis(triphenylphosphine)palladium (55 mg) and aqueous solution of sodium carbonate (2M, 0.92 ml), and the mixture
35 was stirred at 80°C for 2 hours under nitrogen. The mixture

was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel

5 (hexane/ethyl acetate = 2/1) to give methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]-2-methyl-1,1'-biphenyl-4-carboxylate (320 mg).

(+)ESI-MS (m/z): 524 (M+H)⁺

10 Example 8

The following compounds were obtained according to a similar manner to that of Example 6.

(1) 5-Chloro-6-[4-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]nicotinic acid
15 hydrochloride

NMR (DMSO-d₆, δ): 3.04-3.32 (6H, m), 5.03-5.07 (1H, m),
5.14 (1H, br), 7.18 (2H, d, J=8.5Hz), 7.33-7.48
(6H, m), 8.38 (1H, d, J=2.0Hz), 8.54 (1H, d,
20 J=2.0Hz), 9.00 (1H, br), 9.35 (1H, br)

(-)ESI-MS (m/z): 445 (M-HCl-H)⁻

(2) 4'-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-ethyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid
25 hydrochloride

NMR (DMSO-d₆, δ): 2.28 (1H, s), 3.01-3.27 (6H, m),
5.00-5.04 (1H, m), 6.36 (1H, br), 7.28-7.48 (9H,
m), 7.79-7.90 (2H, m), 9.02 (1H, br)

(-)ESI-MS (m/z): 408 (M-HCl-H)⁻

30

Example 9

To a solution of tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-(4-hydroxyphenyl)ethyl]carbamate (600 mg) and potassium carbonate (254 mg) in dimethylsulfoxide (6.0
35 ml) was added methyl 5,6-dichloro-3-pyridinecarboxylate (347

mg), and the mixture was stirred at room temperature for 12 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give methyl 6-[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]-5-chloronicotinate (770 mg).

(+)ESI-MS (m/z): 561 (M+H)⁺

Example 10

Under nitrogen at 5°C, to a solution of tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-(4-hydroxyphenyl)ethyl]carbamate (1.5 g), ethyl [3-(hydroxymethyl)phenoxy]acetate (885 mg) and triphenyl phosphine (1.1 g) in tetrahydrofuran (30 ml) was added diethyl azodicarboxylate (0.66 ml). The mixture was stirred at room temperature for 12 hours and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give ethyl [3-[[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]methyl]-phenoxy]acetate (1.04 g).

(+)ESI-MS (m/z): 585 (M+H)⁺

Example 11

To a solution of ethyl [3-[[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenoxy]methyl]phenoxy]acetate (1.0 g) in tetrahydrofuran (5.0 ml) was added 4N hydrochloride in dioxane (4.3 ml). The mixture was stirred at room temperature for 8 hours and evaporated under reduced pressure. The residue was diluted with ethyl acetate and saturated sodium bicarbonate solution. The organic layer

was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (methanol/chloroform = 1/20) to give ethyl [3-[[4-[2-[[2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]-methyl]phenoxy]acetate (632 mg).

(+)ESI-MS (m/z): 484 (M+H)⁺

The object compound above was hydrolyzed in a conventional manner to give sodium [3-[[4-[2-[[2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenoxy]methyl]phenoxy]acetate (492 mg).

NMR (DMSO-d₆, δ): 2.56-2.73 (6H, m), 4.09 (2H, s), 4.58-4.64 (1H, m), 4.98 (2H, s), 6.72-6.77 (1H, m), 6.85-6.91 (4H, m), 7.08 (2H, d, J=8.5Hz), 7.17-7.26 (4H, m), 7.38 (1H, s)

(-)ESI-MS (m/z): 454 (M-Na-H)⁻

Example 12

The following compounds were obtained according to a similar manner to that of Example 3.

(1) tert-Butyl [4-[[4-[2-[(tert-butoxycarbonyl)[2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]amino]phenoxy]acetate

(+)ESI-MS (m/z): 597 (M+H)⁺

(2) tert-Butyl [4-[[4-[2-[(tert-butoxycarbonyl)[2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-(methyl)amino]phenoxy]acetate

(+)ESI-MS (m/z): 611 (M+H)⁺

Example 13

To a solution of tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-[4-[(4-hydroxyphenyl)thio]phenyl]ethyl]-

carbamate (195 mg) and potassium carbonate (59 mg) in N,N-dimethylformamide (3 ml) was added tert-butyl bromoacetate (84 mg), and the mixture was stirred at room temperature for 3 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give tert-butyl [4-[[4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]thio]-phenoxy]acetate (168 mg).

(+)ESI-MS (m/z): 636 (M+Na)⁺

Preparation 12

To a solution of 4-bromo-2-fluorobenzoate (1.5 g) in N,N-dimethylformamide (30 ml) was added bis(pinacolato)-diboron (1.8 g), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloridedichloromethane complex (1:1) (263 mg) and potassium acetate (1.9 g), and the mixture was stirred at 100°C for 18 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 5/1) to give methyl 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (350 mg).

(+)ESI-MS (m/z): 303 (M+Na)⁺

Preparation 13

To a solution of methyl 4-bromo-2-methoxybenzoate (2.0 g) in 1,4-dioxane (40 ml) was added bis(pinacolato)diboron (2.07 g), dichlorobis(triphenylphosphine)palladium(II) (286 mg) and potassium acetate (2.4 g), and the mixture was stirred at 95°C for 10 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer

was separated, washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give methyl 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (2.0 g).

(+)ESI-MS (m/z): 293 (M+H)⁺.

Preparation 14

To a suspension of methyl 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (2.0 g) in acetone (70 ml) and water (70 ml) was added ammonium acetate (1.11 g) and sodium periodate (3.08 g), and the mixture was stirred at room temperature for 15 hours. The solvent was evaporated and the residue was diluted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure to give [3-methoxy-4-(methoxycarbonyl)phenyl]-boronic acid (1.4 g).

(+)ESI-MS (m/z): 209 (M-H)⁻.

Preparation 15

The following compounds were obtained according to a similar manner to that of Preparation 14.

(1) [3-Fluoro-4-(methoxycarbonyl)phenyl]boronic acid

(+)ESI-MS (m/z): 197 (M-H)⁻

(2) [2-Chloro-4-(methoxycarbonyl)phenyl]boronic acid

(+)ESI-MS (m/z): 213 (M-H)⁻

(3) [4-(Ethoxycarbonyl)-2-methoxyphenyl]boronic acid

(+)ESI-MS (m/z): 223 (M-H)⁻

Preparation 16

To a solution of ethyl 3-methoxy-4-[[[(trifluoromethyl)-

sulfonyl]oxy]benzoate (1.52 g) in 1,4-dioxane (35 ml) was added bis(pinacolato)diboron (1.18 g), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloridedichloromethane complex (1:1) (309 mg) and potassium acetate (1.36 g), and
 5 the mixture was stirred at 100°C for 10 hours under nitrogen.

The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate
 10 = 5/1) to give ethyl 3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (700 mg).

(+)ESI-MS (m/z): 293 (M+H)⁺

Preparation 17

15 The following compound was obtained according to a similar manner to that of Preparation 16.

Methyl 3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate

20 (+)ESI-MS (m/z): 297 (M+H)⁺

Preparation 18

To a solution of tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-(4-hydroxyphenyl)ethyl]carbamate (5.0 g) and
 25 2,6-lutidine (2.97 ml) in dichloromethane (75 ml) was added trifluoromethanesulfonic anhydride (2.36 ml) dropwise at -70°C under nitrogen and the mixture was stirred at -70°C for 30 minutes. The mixture was allowed to warm to room temperature and evaporated under reduced pressure. The
 30 residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with saturated sodium bicarbonate solution and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel
 35 (hexane/ethyl acetate = 2/1) to give 4-[2-[(tert-

butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]phenyl trifluoromethanesulfonate (6.6 g).

(+)ESI-MS (m/z): 546 (M+Na)⁺

5 Preparation 19

To a solution of methyl 4-bromo-2-methylbenzoate (6.9 g) in 1,4-dioxane (150 ml) was added bis(pinacolato)diboron (8.03 g), dichlorobis(triphenylphosphine)palladium(II) (1.69 g) and potassium acetate (8.87 g), and the mixture was stirred at 95°C for 2 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with 1N hydrochloric acid and brine, dried over magnesium sulfate and evaporated. To a suspension of the crude product (11 g) in acetone (200 ml) and water (200 ml) was added ammonium acetate (5.1 g) and sodium periodate (14.1 g), and the mixture was stirred at room temperature for 6 hours. The solvent was evaporated, and the mixture was diluted with ethyl acetate. The organic layer was separated, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The resultant solid was triturated with diisopropyl ether to give [3-methyl-4-(methoxycarbonyl)phenyl]boronic acid (2.65 g).

(+)ESI-MS (m/z): 193 (M-H)⁻

25

Preparation 20

To a solution of 4-hydroxy-2,3-dimethylbenzaldehyde (1.9 g) and pyridine (5.12 ml) in dichloromethane (40 ml) was added trifluoromethanesulfonic anhydride (2.34 ml) under nitrogen and the mixture was stirred at room temperature for 30 minutes and evaporated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was separated, washed with saturated sodium bicarbonate solution and brine, dried over magnesium sulfate and evaporated under reduced pressure to give 4-

35

formyl-2,3-dimethylphenyl trifluoromethanesulfonate (2.7 g).

(+)ESI-MS (m/z): 281 (M-H)⁻

Preparation 21

5 To a solution of 4-formyl-2,3-dimethylphenyl
trifluoromethanesulfonate (2.5 g) in 1,4-dioxane (50 ml) was
added bis(pinacolato)diboron (2.47 g), 1,1'-bis(diphenyl-
phosphino)ferrocene-palladium(II)dichloridedichloromethane
10 complex (1:1) (1.09 g) and potassium acetate (2.61 g), and
the mixture was stirred at 90°C for 5 hours under nitrogen.
The mixture was diluted with ethyl acetate and water. The
organic layer was separated, washed with 1N hydrochloric
acid and brine, dried over magnesium sulfate and evaporated.
To a suspension of the crude product in acetone (80 ml) and
15 water (80 ml) was added ammonium acetate (1.4 g) and sodium
periodate (3.95 g), and the mixture was stirred at room
temperature for 6 hours. The solvent was evaporated, and the
mixture was diluted with ethyl acetate. The organic layer
was separated, washed with water and brine, dried over
20 magnesium sulfate and evaporated under reduced pressure.
The residue was purified by column chromatography on silica
gel (hexane/ethyl acetate = 1/1) to give (4-formyl-2,3-
dimethylphenyl)boronic acid (560 mg).

(+)ESI-MS (m/z): 177 (M-H)⁻

25

Preparation 22

To a solution of N-benzyl-N-[2-(4-bromophenyl)ethyl]-
carbamate (1.3 g) in 1,2-dimethoxyethane (20 ml) was added
[4-(methoxycarbonyl)-2-methylphenyl]boronic acid (792 mg),
30 tetrakis(triphenylphosphine)palladium (360 mg) and aqueous
solution of sodium carbonate (2M, 4.1 ml), and the mixture
was stirred at 80°C for 2 hours under nitrogen. The mixture
was diluted with ethyl acetate and water. The organic layer
was separated, washed with brine, dried over magnesium
35 sulfate and evaporated under reduced pressure. The residue

was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give methyl 4'-[2-[[{(benzyloxy)carbonyl]amino]ethyl]-2-methyl-1,1'-biphenyl-4-carboxylate (660 mg).

5 (+)ESI-MS (m/z): 426 (M+Na)⁺

Preparation 23

To a solution of 2,2,2-trifluoro-N-[3-(4-iodophenyl)-propyl]acetamide (2.5 g) in 1,2-dimethoxyethane (15 ml) was
10 added [4-(methoxycarbonyl)phenyl]boronic acid (1.51 g), tetrakis(triphenylphosphine)palladium (809 mg) and aqueous solution of sodium carbonate (2M, 7 ml), and the mixture was stirred at 75°C for 10 hours under nitrogen. The mixture
15 was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give methyl 4'-[3-[(trifluoroacetyl)amino]propyl]-1,1'-biphenyl-4-carboxylate (920 mg).

20 MS (m/z): 366 (M+H)

Preparation 24

The following compound was obtained according to a similar manner to that of Preparation 23.

25

Ethyl 4'-[2-[[{(benzyloxy)carbonyl]amino]ethyl]-2-methoxy-1,1'-biphenyl-4-carboxylate

MS (m/z): 434 (M+H)

30 Preparation 25

A mixture of methyl 4'-[3-[(trifluoroacetyl)amino]propyl]-1,1'-biphenyl-4-carboxylate (920 mg), 4N hydrochloride in ethanol (2 ml) and ethanol (2 ml) was refluxed for 18 hours. The mixture was evaporated in vacuo.
35 The residue was diluted with ethyl acetate and saturated

aqueous sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (chloroform:methanol = 100:1) to give ethyl 4'-(3-aminopropyl)-1,1'-biphenyl-4-carboxylate (200 mg) as a colorless foam.

MS (m/z): 284 (M+H)

Preparation 26

To a solution of ethyl (1R)-1-(6-chloro-3-pyridyl)-2-[[3-(4-iodophenyl)propyl]amino]ethanol (2.0 g) in tetrahydrofuran (3.5 ml) was added di-tert-butyl dicarbonate (53 mg), and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give tert-butyl [(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl][3-(4-iodophenyl)propyl]-carbamate (2.62 g).

MS (m/z): 517 (M+H)

Preparation 27

To a solution of 2,2,2-trifluoro-N-[(1R)-2-(4-iodophenyl)-1-methylethyl]acetamide in dioxane (10 ml) was added 1N sodium hydroxide (12 ml) and the mixture was stirred for 1 hour at room temperature. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated to give [(1R)-2-(4-iodophenyl)-1-methylethyl]amine (2.34 g) as a yellow oil.

MS (m/z): 262 (M+H)

Preparation 28

A solution of [(1R)-2-(4-iodophenyl)-1-methylethyl]-amine (1.0 g) and 2-chloro-5-[(2R)-2-oxiranyl]pyridine (298 mg) in ethanol (10 ml) was refluxed for 18 hours. The

mixture was evaporated in vacuo. To the residue was added di-tert-butyl dicarbonate (418 mg) and tetrahydrofuran (10 ml) and the mixture was stirred at room temperature for 2 hours and then evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give tert-butyl [(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl][(1R)-2-(4-iodophenyl)-1-methylethyl]carbamate (700 mg).

MS (m/z): 517 (M+H)

10

Preparation 29

The following compound was obtained according to a similar manner to that of Preparation 28.

15

tert-Butyl [(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl][2-(4-hydroxyphenyl)ethyl]carbamate

MS (m/z): 393 (M+H)

Preparation 30

20

Under nitrogen at -60°C, to a solution of tert-butyl [2-(4-hydroxyphenyl)ethyl][(2R)-2-hydroxy-2-(3-pyridyl)-ethyl]carbamate (570 mg) and 2,6-lutidine (0.22 ml) in dichloromethane (10 ml) was added trifluoromethanesulfonic anhydride (0.28 ml), and the mixture was stirred at the same temperature for 1 hour. The resulting mixture was poured into aqueous ammonia and the aqueous mixture was extracted with ethyl acetate. The organic layer was washed successively with 1N hydrochloric acid, water, saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1:1) to give 4-[2-[(tert-butoxycarbonyl][(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]-ethyl]phenyl trifluoromethanesulfonate (640 mg) as a colorless foam.

35

MS (m/z): 491 (M+H)

Preparation 31

The following compound was obtained according to a
5 similar manner to that of Preparation 30.

4-[2-[(tert-Butoxycarbonyl)[(2R)-2-hydroxy-2-(3-
chlorophenyl)ethyl]amino]propyl]phenyl
trifluoromethanesulfonate

10 MS (m/z): 538 (M+H)

Preparation 32

To a solution of 2,2,2-trifluoro-N-[(1R)-1-methyl-2-
phenylethyl]acetamide (3.75 g) in acetic acid (32 ml) -
15 water (6.5 ml) - sulfuric acid (0.97 ml) were added iodine
(1.65 g) and periodic acid dihydrate (740 mg) at room
temperature, and the mixture was heated to 60 - 80°C for 5
hours. After being allowed to cool to room temperature, the
mixture was partitioned between hexane/ethyl acetate and
20 water. The organic layer was separated, washed successively
with water, sodium sulfite solution, water and brine, dried
over magnesium sulfate, and filtered. The filtrate was
concentrated and the residue was recrystallized from
diisopropyl ether (44 ml) to give 2,2,2-trifluoro-N-[(1R)-2-
25 (4-iodophenyl)-1-methylethyl]acetamide (2.15 g) as a
colorless needle.

NMR (CDCl₃, δ): 1.21 (3H, d, J=7Hz), 2.74 (1H, dd, J=14,
7Hz), 2.85 (1H, dd, J=14, 6Hz), 4.26 (1H, m), 6.04
(1H, br s), 6.92 (2H, d, J=8Hz), 7.65 (2H, d,
30 J=8Hz)

(+)ESI-MS (m/z): 380 (M+Na)⁺

Preparation 33

The following compound was obtained according to a
35 similar manner to that of Preparation 32.

2,2,2-Trifluoro-N-[3-(4-iodophenyl)propyl]acetamide

NMR (CDCl₃, δ): 1.90 (2H, quintet, J=7Hz), 2.62 (2H, t, J=7Hz), 3.38 (2H, q, J=7Hz), 6.26 (1H, br s), 6.93 (2H, d, J=8Hz), 7.62 (2H, d, J=8Hz)

(+)ESI-MS (m/z): 380 (M+Na)⁺

Preparation 34

To a mixture of 3-(4-hydroxyphenyl)propanoic acid (15.0 g), (1R)-2-amino-1-(3-chlorophenyl)ethanol hydrochloride (18.8 g), and 1-hydroxybenzotriazole (14.6 g) in N,N-dimethylformamide (100 ml) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (26.0 g), and the mixture was stirred at room temperature for 3 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed successively with sodium bicarbonate solution and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-3-(4-hydroxyphenyl)propanamide (11.61 g) as a white amorphous powder.

MS (m/z): 320 (M+H)

Preparation 35

To a solution of N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-3-(4-hydroxyphenyl)propanamide (11.61 g) in tetrahydrofuran (70 ml) was added borane-methyl sulfide complex (10M, 11.9 ml) at 0°C, and the mixture was heated to 80°C for 1 hour. After being allowed to cool to room temperature, the mixture was added 2N hydrochloric acid (20 ml) at 0°C. The mixture was heated to 80°C for 1 hour. After being allowed to cool to room temperature, the mixture was added 1N sodium hydroxide (40 ml) and di-tert-butyl

dicarbonate (8.72 g) and stirred for 1 hour at room temperature. The mixture was partitioned between hexane/ethyl acetate and water. The organic layer was separated, washed successively with water, sodium sulfite solution, water and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give tert-butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][3-(4-hydroxyphenyl)propyl]carbamate (11.36 g) as a white powder.

MS (m/z): 406 (M+H)

Preparation 36

A mixture of methyl 4'-[2-[(benzyloxy)carbonyl]-amino]ethyl]-2-methyl-1,1'-biphenyl-4-carboxylate (650 mg), ammonium formate (500 mg) and palladium on carbon powder (400 mg) in methanol (10 ml) and water (1.0 ml) was refluxed for 2 hours. The reaction mixture was filtrated and poured into water and extracted with chloroform. The organic layer was washed with brine, dried over magnesium sulfate and evaporated to give methyl 4'-(2-aminoethyl)-2-methyl-1,1'-biphenyl-4-carboxylate (380 mg).

(+)ESI-MS (m/z): 270 (M+H)⁺

Preparation 37

The following compounds were obtained according to a similar manner to that of Preparation 36.

(1) Ethyl 4'-(2-aminoethyl)-2-methoxy-1,1'-biphenyl-4-carboxylate

MS (m/z): 300 (M+H)

(2) tert-Butyl [2-(4-hydroxyphenyl)ethyl][(2R)-2-hydroxy-2-(3-pyridyl)ethyl]carbamate

MS (m/z): 359 (M+H)

Preparation 38

The following compound was obtained according to a similar manner to that of Example 14.

5

tert-Butyl [(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][2-(4'-formyl-2',3'-dimethyl-1,1'-biphenyl-4-yl)ethyl]carbamate
(+)ESI-MS (m/z): 530 (M+Na)⁺

10 Example 14

To a solution of tert-butyl [2-(4-bromophenyl)ethyl]-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (365 mg) in 1,2-dimethoxyethane (6 ml) was added [4-(ethoxycarbonyl)-2-methoxyphenyl]boronic acid (216 mg),
15 tetrakis(triphenylphosphine)palladium (46 mg) and aqueous solution of sodium carbonate (2M, 0.85 ml), and the mixture was stirred at 80°C for 4 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium
20 sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to give ethyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-amino]ethyl]-2-methoxy-1,1'-biphenyl-4-carboxylate (222 mg).
25 MS (m/z): 554 (M+H)⁺

Example 15

The following compounds were obtained according to a similar manner to that of Example 14.

30

(1) 4'-[(2R)-2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid hydrochloride
NMR (DMSO-d₆, δ): 1.14 (3H, d, J=6.4Hz), 2.8-3.8 (5H,
35 m), 3.92 (3H, s), 5.0-5.3 (1H, m), 6.3-6.4 (1H, m),

7.2-7.8 (10H, m), 8.13 (1H, br s), 8.85 (1H, br s),
9.42 (1H, br s)

MS (m/z): 440 (M+H)

- 5 (2) 4'-[(2R)-2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]propyl]-2-methoxy-1,1'-biphenyl-4-carboxylic acid
hydrochloride

NMR (DMSO-d₆, δ): 1.17 (3H, d, J=6.4Hz), 2.8-3.8 (5H,
m), 3.83 (3H, s), 5.0-5.2 (1H, m), 6.3-6.4 (1H, m),
10 7.2-7.8 (10H, m), 8.11 (1H, br s), 8.86 (1H, br s),
9.37 (1H, br s)

MS (m/z): 440 (M+H)

- 15 (3) 4'-[(2R)-2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]propyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid
hydrochloride

NMR (DMSO-d₆, δ): 1.17 (3H, d, J=6.4Hz), 2.28 (3H, s),
2.8-3.8 (5H, m), 5.0-5.3 (1H, m), 6.3-6.4 (1H, m),
7.2-7.6 (8H, m), 7.7-7.9 (2H, m), 8.11 (1H, br s),
20 8.86 (1H, br s), 9.39 (1H, br s)

MS (m/z): 424 (M+H)

- 25 (4) 4'-[(2R)-2-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid
hydrochloride

NMR (DMSO-d₆, δ): 1.16 (3H, d, J=6.4Hz), 2.8-3.8 (5H,
m), 3.91 (3H, s), 5.0-5.3 (1H, m), 6.3-6.4 (1H, m),
7.2-7.8 (11H, m), 8.77 (1H, br s), 9.13 (1H, br s)

MS (m/z): 440 (M+H)

30

- (5) 4'-[(2R)-2-[[(2R)-2-Phenyl-2-hydroxyethyl]amino]-
propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid
hydrochloride

NMR (DMSO-d₆, δ): 1.15 (3H, d, J=6.4Hz), 2.8-3.8 (5H,
35 m), 3.92 (3H, s), 5.0-5.2 (1H, m), 6.3-6.4 (1H, m),

7.2-7.6 (9H, m), 7.7-7.9 (3H, m), 8.81 (1H, br s),
9.31 (1H, br s)

MS (m/z): 406 (M+H)

- 5 (6) 4'-[(2R)-2-[[(2R)-2-Phenyl-2-hydroxyethyl]amino]-
propyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid
hydrochloride

NMR (DMSO-d₆, δ): 1.17 (3H, d, J=6.4Hz), 2.28 (3H, s),
2.8-3.8 (5H, m), 5.0-5.2 (1H, m), 6.3-6.4 (1H, m),
10 7.2-7.6 (9H, m), 7.7-7.9 (3H, m), 8.81 (1H, br s),
9.24 (1H, br s)

MS (m/z): 390 (M+H)

- (7) 4'-[(2R)-2-[[(2S)-2-Phenyl-2-hydroxyethyl]amino]-
15 propyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid
hydrochloride

NMR (DMSO-d₆, δ): 1.19 (3H, d, J=6.4Hz), 2.27 (3H, s),
2.8-3.8 (5H, m), 5.0-5.2 (1H, m), 6.2-6.3 (1H, m),
7.2-7.6 (9H, m), 7.7-7.9 (3H, m), 8.80 (1H, br s),
20 9.35 (1H, br s)

MS (m/z): 390 (M+H)

- (8) 4'-[(2R)-2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-
25 aminopropyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic
acid hydrochloride

NMR (DMSO-d₆, δ): 1.14 (3H, d, J=6.4Hz), 1.30 (6H, d,
J=5.8Hz), 2.8-3.8 (5H, m), 4.6-4.9 (1H, m), 5.0-
5.3 (1H, m), 6.2-6.4 (1H, m), 7.2-7.8 (11H, m),
8.82 (1H, br s), 9.24 (1H, br s)

30 MS (m/z): 468 (M+H)

- (9) 4'-[(2R)-2-[[(2R)-2-Phenyl-2-hydroxyethyl]amino]-
propyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid
hydrochloride

35 NMR (DMSO-d₆, δ): 1.12 (3H, d, J=6.4Hz), 1.30 (6H, d,

J=5.8Hz), 2.8-3.8 (5H, m), 4.6-4.9 (1H, m), 5.0-5.3 (1H, m), 6.2-6.4 (1H, m), 7.2-7.8 (12H, m), 8.82 (1H, br s)

MS (m/z): 434 (M+H)

5

(10) 4'-[(2R)-2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]propyl]-3-cyclohexyloxy-1,1'-biphenyl-4-carboxylic acid hydrochloride

10 NMR (DMSO-d₆, δ): 1.14 (3H, d, J=6.4Hz), 1.2-2.0 (10H, m), 2.8-3.8 (5H, m), 4.65 (1H, m), 5.0-5.2 (1H, m), 6.3-6.4 (1H, m), 7.2-7.9 (11H, m), 8.79 (1H, br s), 9.10 (1H, br s)

MS (m/z): 508 (M+H)

15 (11) 4'-[(2R)-2-[(2R)-2-Phenyl-2-hydroxyethyl]amino]-propyl]-3-cyclohexyloxy-1,1'-biphenyl-4-carboxylic acid hydrochloride

20 NMR (DMSO-d₆, δ): 1.14 (3H, d, J=6.4Hz), 1.2-2.0 (10H, m), 2.8-3.8 (5H, m), 4.65 (1H, m), 4.9-5.1 (1H, m), 6.23 (1H, m), 7.1-7.9 (12H, m)

MS (m/z): 474 (M+H)

(12) Methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylate

25

(+)ESI-MS (m/z): 562 (M+Na)⁺

(13) Methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2-chloro-1,1'-biphenyl-4-carboxylate

30

(+)ESI-MS (m/z): 544 (M+H)⁺

Example 16

35 To a solution of 4-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl

trifluoromethanesulfonate (300 mg) in 1,2-dimethoxyethane (5 ml) was added [3-fluoro-4-(methoxycarbonyl)phenyl]boronic acid (125 mg), tetrakis(triphenylphosphine)palladium (53 mg) and aqueous solution of sodium carbonate (2M, 0.6 ml), and the mixture was stirred at 80°C for 2 hours under nitrogen. The mixture was diluted with ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 3/1) to give methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-3-fluoro-1,1'-biphenyl-4-carboxylate (230 mg).

(+)ESI-MS (m/z): 528 (M+H)⁺

15

Example 17

The following compound was obtained according to a similar manner to that of Example 16.

Methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-3-methyl-1,1'-biphenyl-4-carboxylate

(+)ESI-MS (m/z): 546 (M+Na)⁺

25 Example 18

To a solution of ethyl 4'-[2-[(tert-butoxycarbonyl)-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2-methoxy-1,1'-biphenyl-4-carboxylate (220 mg) in ethanol (2.0 ml) was added 1N aqueous sodium hydroxide solution (1.2 ml), and the mixture was stirred at 40°C for 3 hours. The solvent was removed by evaporation, and the aqueous solution was acidified with 1N hydrochloric acid and extracted with ethyl acetate (30 ml x 2). The combined organic layers were washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure to give a benzoic acid

product. To a solution of the product in tetrahydrofuran (1.5 ml) was added 4N hydrochloride in dioxane (1.0 ml), and the mixture was stirred at room temperature for 12 hours. The resultant solid was collected by filtration and dried to give 4'-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-ethyl]-2-methoxy-1,1'-biphenyl-4-carboxylic acid hydrochloride (83 mg).

NMR (DMSO-d₆, δ): 3.02-3.27 (6H, m), 3.82 (3H, s),
4.98-5.02 (1H, m), 6.35 (1H, br), 7.30-7.64 (11H,
m), 9.05 (1H, br)

(-)ESI-MS (m/z): 424 (M-HCl-H)⁻

Example 19

The following compounds were obtained according to a similar manner to that of Example 18.

(1) 4'-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-ethyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid hydrochloride

NMR (DMSO-d₆, δ): 3.01-3.34 (6H, m), 3.92 (3H, s),
5.02-5.06 (1H, m), 6.37 (1H, br), 7.26-7.48 (9H,
m), 7.74 (2H, d, J=7.9Hz), 9.25 (1H, br)

(-)ESI-MS (m/z): 424 (M-HCl-H)⁻

(2) 2-Chloro-4'-[2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]-1,1'-biphenyl-4-carboxylic acid hydrochloride

NMR (DMSO-d₆, δ): 3.01-3.34 (6H, m), 4.99-5.03 (1H, m),
6.36 (1H, br), 7.37-7.55 (9H, m), 7.93-8.03 (2H,
m), 9.10 (1H, br)

(-)ESI-MS (m/z): 424 (M-HCl-H)⁻

(3) 4'-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-ethyl]-3-fluoro-1,1'-biphenyl-4-carboxylic acid hydrochloride

NMR (DMSO- d_6 , δ): 3.01-3.33 (6H, m), 4.98-5.03 (1H, m),
6.34 (1H, br), 7.35-7.47 (6H, m), 7.61-7.98 (5H,
m), 9.10 (1H, br)

(-)-ESI-MS (m/z): 412 (M-HCl-H)⁻

5

(4) 4'-[2-[[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-
ethyl]-3-methyl-1,1'-biphenyl-4-carboxylic acid
hydrochloride

10 NMR (DMSO- d_6 , δ): 2.60 (3H, s), 3.01-3.34 (6H, m),
4.98-5.02 (1H, m), 6.34 (1H, br), 7.36-7.60 (8H,
m), 7.72 (2H, d, J=8.0Hz), 7.91 (1H, d, J=8.0Hz),
9.25 (1H, br)

(-)-ESI-MS (m/z): 408 (M-HCl-H)⁻

15 Example 20

To a solution of tert-butyl [(2R)-2-(3-chlorophenyl)-2-
hydroxyethyl][2-(4'-formyl-2',3'-dimethyl-1,1'-biphenyl-4-
yl)ethyl]carbamate in acetonitrile (2.5 ml) and pH 4 buffer
solution (sodium dihydrogenphosphate) (1.3 ml) was added 30%
20 hydrogen peroxide solution (60 μ l) and 80% sodium chlorite
(128 mg) below 10°C. The reaction mixture was stirred at
40°C for 1.5 hours. The mixture was diluted with ethyl
acetate, washed with water and brine, dried over magnesium
sulfate and evaporated under reduced pressure to give a
25 benzoic acid product. To a solution of the product in
tetrahydrofuran (1.0 ml) was added 4N hydrochloride in
dioxane (1.18 ml), and the mixture was stirred at room
temperature for 12 hours. The resultant solid was collected
by filtration and dried to give 4'-[2-[[[(2R)-2-(3-
30 chlorophenyl)-2-hydroxyethyl]amino]ethyl]-2,3-dimethyl-1,1'-
biphenyl-4-carboxylic acid hydrochloride (140 mg).

NMR (DMSO- d_6 , δ): 2.14 (3H, s), 2.45 (3H, s), 3.00-3.34
(6H, m), 4.99-5.03 (1H, m), 6.34 (1H, br), 7.07
(1H, d, J=8.0Hz), 7.05-7.59 (9H, m), 9.25 (1H, br)

35 (-)-ESI-MS (m/z): 422 (M-HCl-H)⁻

Example 21

A solution of ethyl 4'-(3-aminopropyl)-1,1'-biphenyl-4-carboxylate (200 mg), and 2-chloro-5-[(2R)-2-oxiranyl]-pyridine (71.5 mg) in ethanol (10 ml) was refluxed for 18 hours. The mixture was evaporated in vacuo. The residue was purified by column chromatography on silica gel (chloroform:methanol = 100:1) to give ethyl 4'-[3-[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]propyl]-1,1'-biphenyl-4-carboxylate (96 mg) as a colorless foam.

MS (m/z): 439 (M+H)

Example 22

The following compounds were obtained according to a similar manner to that of Example 21.

(1) Methyl 4'-[2-[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]ethyl]-2-methyl-1,1'-biphenyl-4-carboxylate
(+)ESI-MS (m/z): 425 (M+H)⁺

(2) Ethyl 4'-[2-[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]ethyl]-2-methoxy-1,1'-biphenyl-4-carboxylate
MS (m/z): 454 (M⁺)

Example 23

To a solution of ethyl 4'-[3-[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]propyl]-1,1'-biphenyl-4-carboxylate (96 mg) in tetrahydrofuran (3.5 ml) was added di-tert-butyl dicarbonate (53 mg), and the mixture was stirred at room temperature for 30 minutes and then evaporated. To the residue were added 1N sodium hydroxide solution (0.5 ml) and methanol (0.5 ml), and was stirred for 2 hours at room temperature. The residue was diluted with

ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give 4'-[3-[(tert-butoxycarbonyl)[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]-amino]propyl]-1,1'-biphenyl-4-carboxylic acid (100 mg) as a colorless foam.

MS (m/z): 512 (M+H)

10

Example 24

The following compounds were obtained according to a similar manner to that of Example 23.

15 (1) 4'-[2-[(tert-Butoxycarbonyl)[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]ethyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid
(+)ESI-MS (m/z): 509 (M-H)⁻

20 (2) 4'-[2-[(tert-Butoxycarbonyl)[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]ethyl]-2-methoxy-1,1'-biphenyl-4-carboxylic acid
MS (m/z): 527 (M+H)

25 Example 25

4'-[3-[(tert-Butoxycarbonyl)[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]propyl]-1,1'-biphenyl-4-carboxylic acid (100 mg), ammonium formate (50 mg) and palladium on carbon powder (30 mg) in methanol (5 ml) and water (1.0 ml) was refluxed for 30 minutes. The reaction mixture was filtrated and poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. A mixture of the residue was chromatographed (chloroform-methanol) over silica gel to give 4'-[3-[(tert-

35

butoxycarbonyl) [(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]-propyl]-1,1'-biphenyl-4-carboxylic acid (90 mg) as a colorless foam.

MS (m/z): 477 (M+H)

5

Example 26

The following compounds were obtained according to a similar manner to that of Example 25.

- 10 (1) 4'-[2-[(tert-Butoxycarbonyl) [(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid
(+)ESI-MS (m/z): 475 (M-H)⁻
- 15 (2) 4'-[2-[(tert-Butoxycarbonyl) [(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]-2-methoxy-1,1'-biphenyl-4-carboxylic acid
MS (m/z): 493 (M+H)
- 20 (3) 4'-[3-[(tert-Butoxycarbonyl) [(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]propyl]-2-methoxy-1,1'-biphenyl-4-carboxylic acid
MS (m/z): 507 (M+H)
- 25 (4) 4'-[(2R)-2-[(tert-Butoxycarbonyl) [(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]propyl]-1,1'-biphenyl-4-carboxylic acid
MS (m/z): 477 (M+H)

30 Example 27

A solution of tert-butyl 4'-[3-[(tert-butoxycarbonyl)-[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]propyl]-1,1'-biphenyl-4-carboxylic acid (90 mg) and 4N hydrochloride in dioxane (5.0 ml) was stirred at room temperature for 24
35 hours. The resultant solid was collected by filtration and

dried to give 4'-[3-[[[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]-amino]propyl]-1,1'-biphenyl-4-carboxylic acid dihydrochloride (80 mg) as a white solid.

5 NMR (DMSO-d₆, δ): 2.90-3.90 (8H, m), 5.10-5.20 (1H, m),
7.35 (1H, d, J=8Hz), 7.65-7.85 (6H, m), 8.05 (1H, d, J=8Hz), 8.25 (1H, d, J=8Hz), 8.70-8.85 (2H, m)
MS (m/z): 377 (M+H)

Example 28

10 The following compounds were obtained according to a similar manner to that of Example 27.

(1) 4'-[2-[[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid
15 dihydrochloride
NMR (DMSO-d₆, δ): 3.10-3.80 (6H, m), 3.90 (3H, s),
5.10-5.20 (1H, m), 7.40-7.70 (7H, m), 7.8-7.90 (1H, m), 8.25 (1H, d, J=8Hz), 8.70-8.85 (2H, m)
(-)ESI-MS (m/z): 375 (M-2HCl-H)⁻

20 (2) 4'-[2-[[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]-2-methoxy-1,1'-biphenyl-4-carboxylic acid dihydrochloride
NMR (DMSO-d₆, δ): 3.10-3.80 (6H, m), 3.90 (3H, s),
25 5.10-5.20 (1H, m), 7.40-7.70 (7H, m), 7.80-7.90 (1H, m), 8.25 (1H, d, J=8Hz), 8.70-8.85 (2H, m)
MS (m/z): 393 (M+H)

(3) 4'-[3-[[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]-propyl]-2-methoxy-1,1'-biphenyl-4-carboxylic acid dihydrochloride
30 NMR (DMSO-d₆, δ): 2.90-3.90 (8H, m), 3.95 (3H, s),
5.10-5.20 (1H, m), 7.35 (1H, d, J=8Hz), 7.65-7.85 (6H, m), 8.05 (1H, d, J=8Hz), 8.25 (1H, d, J=8Hz),
35 8.70-8.85 (2H, m)

MS (m/z): 407 (M+H)

- (4) 2-Chloro-4'-[2-[[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]-amino]ethyl]-1,1'-biphenyl-4-carboxylic acid
dihydrochloride

NMR (DMSO-d₆, δ): 3.10-3.80 (6H, m), 5.10-5.20 (1H, m),
7.40-7.70 (7H, m), 7.90-8.10 (2H, m), 8.70-8.85
(2H, m)

MS (m/z): 397 (M+H)

- (5) 4'-[(2R)-2-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]-propyl]-1,1'-biphenyl-4-carboxylic acid dihydrochloride

NMR (DMSO-d₆, δ): 1.70 (3H, d, J=6Hz), 3.30-3.90 (6H,
m), 5.10-5.20 (1H, m), 7.40-7.70 (7H, m), 7.80-
7.90 (1H, m), 8.25 (1H, d, J=8Hz), 8.70-8.85 (2H,
m)

MS (m/z): 377 (M+H)

- (6) 4'-[3-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-propyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid
hydrochloride

NMR (DMSO-d₆, δ): 2.00-2.15 (2H, m), 2.30 (3H, s),
2.60-3.30 (6H, m), 5.00-5.10 (1H, m), 7.20-7.60
(9H, m), 7.75-7.90 (2H, m)

MS (m/z): 424 (M+H)

Example 29

The following compounds were obtained according to a similar manner to that of Example 23.

- (1) Ethyl 4'-[3-[(tert-butoxycarbonyl)[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]propyl]-2-methoxy-1,1'-biphenyl-4-carboxylate

MS (m/z): 569 (M+H)

- (2) Methyl 4'-[2-[(tert-butoxycarbonyl)[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]-2-chloro-1,1'-biphenyl-4-carboxylate
MS (m/z): 512 (M+H)
- 5
- (3) Methy 4'-[(2R)-2-[(tert-butoxycarbonyl)[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]propyl]-1,1'-biphenyl-4-carboxylate
MS (m/z): 524 (M+H)
- 10
- (4) Methyl 4'-[3-[(tert-butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-2-methyl-1,1'-biphenyl-4-carboxylate
MS (m/z): 538 (M+H)
- 15
- (5) 4'-[(2R)-2-[[2-(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]propyl]-3-methoxy-1,1'-biphenyl-4-carboxylic acid dihydrochloride
NMR (DMSO-d₆, δ): 1.14 (3H, d, J=6.4Hz), 2.8-3.8 (5H, m), 3.92 (3H, s), 5.1-5.3 (1H, m), 7.2-7.5 (4H, m), 7.7-7.9 (4H, m), 8.2-8.4 (1H, m), 8.8-9.0 (2H, m), 9.36 (1H, br s)
MS (m/z): 407 (M+H)
- 20
- (6) 4'-[(2R)-2-[[2-(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]propyl]-2-methoxy-1,1'-biphenyl-4-carboxylic acid dihydrochloride
NMR (DMSO-d₆, δ): 1.14 (3H, d, J=6.4Hz), 2.8-3.8 (5H, m), 3.83 (3H, s), 5.1-5.3 (1H, m), 7.2-7.8 (7H, m), 7.8-8.0 (1H, m), 8.2-8.5 (1H, m), 8.7-9.0 (2H, m), 9.02 (1H, br s), 9.36 (1H, br s)
MS (m/z): 407 (M+H)
- 25
- (7) 4'-[(2R)-2-[[2-(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]propyl]-2-methyl-1,1'-biphenyl-4-carboxylic acid
- 30
- 35

dihydrochloride

NMR (DMSO- d_6 , δ): 1.19 (3H, d, $J=6.4\text{Hz}$), 2.48 (3H, s),
 2.8-3.8 (5H, m), 5.1-5.3 (1H, m), 7.2-7.5 (5H, m),
 7.8-8.0 (3H, m), 8.37 (1H, d, $J=8.2\text{Hz}$), 8.78 (1H,
 5 d, $J=4.6\text{Hz}$), 8.87 (1H, s), 9.04 (1H, br s), 9.35
 (1H, br s)

MS (m/z): 391 (M+H)

- (8) 4'-[(2R)-2-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]-
 10 propyl]-3-methyl-1,1'-biphenyl-4-carboxylic acid
 dihydrochloride

NMR (DMSO- d_6 , δ): 1.19 (3H, d, $J=6.4\text{Hz}$), 2.60 (3H, s),
 2.8-3.8 (5H, m), 5.1-5.3 (1H, m), 7.2-8.0 (8H, m),
 8.37 (1H, d, $J=8.2\text{Hz}$), 8.79 (1H, d, $J=4.6\text{Hz}$), 8.87
 15 (1H, s), 9.05 (1H, br s), 9.35 (1H, br s)

MS (m/z): 391 (M+H)

- (9) 4'-[(2R)-2-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]-
 20 propyl]-3-isopropoxy-1,1'-biphenyl-4-carboxylic acid
 dihydrochloride

NMR (DMSO- d_6 , δ): 1.19 (3H, d, $J=6.4\text{Hz}$), 1.31 (6H, d,
 $J=6.0\text{Hz}$), 2.8-3.8 (5H, m), 4.6-4.9 (1H, m), 5.1-
 5.3 (1H, m), 7.2-7.5 (4H, m), 7.6-8.0 (4H, m),
 8.37 (1H, d, $J=8.2\text{Hz}$), 8.80 (1H, d, $J=4.6\text{Hz}$), 8.88
 25 (1H, s), 9.02 (1H, br s), 9.35 (1H, br s)

MS (m/z): 435 (M+H)

- (10) 4'-[(2R)-2-[[(2S)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]-
 30 propyl]-1,1'-biphenyl-4-carboxylic acid dihydrochloride

NMR (DMSO- d_6 , δ): 1.19 (3H, d, $J=6.4\text{Hz}$), 2.8-3.8 (5H,
 m), 5.1-5.3 (1H, m), 7.2-8.1 (8H, m), 8.57 (1H, d,
 $J=7.8\text{Hz}$), 8.81 (1H, d, $J=4.6\text{Hz}$), 8.90 (1H, s),
 9.10 (1H, br s), 9.56 (1H, br s)

MS (m/z): 357 (M-H)

(11) 4'-[(2R)-2-[[(2S)-2-Hydroxy-2-(6-chloro-3-pyridyl)-ethyl]amino]propyl]-1,1'-biphenyl-4-carboxylic acid dihydrochloride

5 NMR (DMSO-d₆, δ): 1.17 (3H, d, J=6.4Hz), 2.8-3.8 (5H, m), 5.1-5.3 (1H, m), 7.39 (2H, d, J=8.0Hz), 7.58 (1H, d, J=8.0Hz), 7.6-8.2 (7H, m), 8.48 (1H, d, J=2.4Hz), 8.86 (1H, br s), 9.22 (1H, br s)

MS (m/z): 409 (M-H)

10 (12) 4'-[(2R)-2-[[(2R)-2-Hydroxy-2-(6-chloro-3-pyridyl)-ethyl]amino]propyl]-1,1'-biphenyl-4-carboxylic acid dihydrochloride

15 NMR (DMSO-d₆, δ): 1.16 (3H, d, J=6.4Hz), 2.8-3.8 (5H, m), 5.1-5.3 (1H, m), 7.38 (2H, d, J=8.0Hz), 7.58 (1H, d, J=8.0Hz), 7.6-8.2 (7H, m), 8.49 (1H, d, J=2.4Hz), 8.86 (1H, br s), 9.45 (1H, br s)

MS (m/z): 409 (M-H)

20 (13) 4'-[(2R)-2-[[(2R)-2-Hydroxy-2-(3-pyridyl)ethyl]amino]propyl]-3-cyclohexyloxy-1,1'-biphenyl-4-carboxylic acid dihydrochloride

25 NMR (DMSO-d₆, δ): 1.15 (3H, d, J=6.4Hz), 1.2-2.0 (10H, m), 2.7-3.8 (5H, m), 4.65 (1H, m), 5.31 (1H, m), 7.2-7.5 (5H, m), 7.6-7.8 (2H, m), 7.9-8.0 (1H, m), 8.45 (1H, m), 8.82 (1H, d, J=2.6Hz), 8.90 (1H, s), 9.07 (1H, br s), 9.43 (1H, br s)

MS (m/z): 475 (M+H)

Example 30

30 To a solution of ethyl 4'-[3-[(tert-butoxycarbonyl)-[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]propyl]-2-methoxy-1,1'-biphenyl-4-carboxylate in ethanol (5.0 ml) was added 1N sodium hydroxide (1.0 ml) and the mixture was stirred for 2 hours at room temperature. The mixture was
35 diluted with ethyl acetate and 1N hydrochloric acid. The

organic layer was separated, washed with brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1/1) to give 4'-[3-[(tert-butoxycarbonyl)[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]propyl]-2-methoxy-1,1'-biphenyl-4-carboxylic acid (100 mg).

MS (m/z): 541 (M+H)

Example 31

The following compounds were obtained according to a similar manner to that of Example 30.

(1) 4'-[2-[(tert-Butoxycarbonyl)[(2R)-2-hydroxy-2-(3-pyridyl)ethyl]amino]ethyl]-2-chloro-1,1'-biphenyl-4-carboxylic acid

MS (m/z): 497 (M+H)

(2) 4'-[(2R)-2-[(tert-Butoxycarbonyl)[(2R)-2-(6-chloro-3-pyridyl)-2-hydroxyethyl]amino]propyl]-1,1'-biphenyl-4-carboxylic acid

MS (m/z): 511 (M+H)


(3) 4'-[3-[(tert-Butoxycarbonyl)[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,1'-biphenyl-4-carboxylic acid

MS (m/z): 524 (M+H)



Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of the formula [I]:



wherein




X is bond, -O-, -OCH₂-, -S- or -N- (in which R⁷ is

hydrogen or lower alkyl),

Y is bond, -O-(CH₂)_n- (in which n is 1, 2, 3 or 4),

-(CH₂)_m- (in which m is 1, 2, 3 or 4),



R¹ is hydrogen or halogen,

R² is hydrogen or an amino protective group,

25 R³ is hydrogen or lower alkyl,

R⁴ is hydrogen or lower alkyl,

R⁵ and R⁸ are each independently hydrogen, halogen,

hydroxy, lower alkyl, lower alkoxy,

cyclo(lower)alkyloxy, amino, mono(or

30 di)(lower)alkylamino, mono(or di or



tri)halo(lower)alkyl, cyano or phenyl,

R⁶ is hydrogen or lower alkyl, and

i is 1 or 2,


provided that when X is bond, is and

35

 is ,
 then R⁵ is not hydrogen,
 or a salt thereof.

5

2. A compound of claim 1, wherein



10


X is bond, -O-, -OCH₂-, -S- or -N- (in which R⁷ is

15

hydrogen or lower alkyl),

Y is bond, -O-(CH₂)_n- (in which n is 1, 2, 3 or 4),
 -(CH₂)_m- (in which m is 1, 2, 3 or 4),

20



R¹ is hydrogen or halogen,

R² is hydrogen,

R³ is hydrogen or lower alkyl,

R⁴ is hydrogen,

25

R⁵ is hydrogen, halogen, hydroxy, lower alkyl, lower
 alkoxy or cyclo(lower)alkyloxy,


R⁶ is hydrogen,

R⁸ is hydrogen or lower alkyl, and


i is 1 or 2.

30

3. A compound of claim 2, wherein



35



X is bond, -O-, -OCH₂-, -S- or -N- (in which R⁷ is

hydrogen or lower alkyl),

Y is bond, -O-(CH₂)_n- (in which n is 1 or 2) or

-(CH₂)_m- (in which m is 1 or 2),

R¹ is hydrogen or halogen,

R² is hydrogen,

R³ is hydrogen or lower alkyl,

R⁴ is hydrogen,

R⁵ is hydrogen, halogen, hydroxy, lower alkyl, or lower alkoxy,


R⁶ is hydrogen,


R⁸ is hydrogen, and


i is 1.


4. A process for preparing a compound of claim 1, or a salt thereof, which comprises,


(i) reacting a compound [II] of the formula:





wherein R¹ and  are each as defined in claim 1, with a compound [III] of the formula:






wherein , X, Y, R², R³, R⁴, R⁵, R⁶, R⁸ and i are each as defined in claim 1, or a salt thereof, to give a compound [I] of the formula:




wherein , , X, Y, R¹, R², R³, R⁴, R⁵, R⁶, R⁸ and i are each as defined in claim 1, or a salt thereof,

(ii) subjecting a compound [Ia] of the formula:




wherein , , X, Y, R¹, R³, R⁴, R⁵, R⁶, R⁸

and i are each as defined in claim 1, and R_a² is an amino protective group, or a salt thereof, to elimination reaction of the amino protective group, to give a compound [Ib] of the formula:



and i are each as defined in claim 1,
5 or a salt thereof,

10




or a salt thereof, to give a compound [Ic] of the formula:




wherein ~~A~~, ~~B~~, Y, R¹, R², R³, R⁴, R⁵, R⁶, R⁸
and i are each as defined in claim 1,
or a salt thereof,

35



wherein A , R^1 , R^2 , R^3 , R^4 and i are each as defined in claim 1,


or a salt thereof, with a compound [VI] of the formula:



wherein B , Y , R^5 , R^6 and R^8 are each as defined in claim 1, and


X_1 is a leaving group,

or a salt thereof, to give a compound [Ic] of the formula:




wherein A , B , Y , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^8 and i are each as defined in claim 1, or a salt thereof, and

(v) reacting a compound [VII] of the formula:




wherein A , R^1 , R^2 , R^3 , R^4 and i are each as defined in claim 1,

X_2 is a leaving group,
or a salt thereof, with a compound [V] of the formula:



wherein B , R^5 , R^6 and R^8 are each as defined in
claim 1,

10 or a salt thereof, to give a compound [Id] of the
formula:



wherein A , B , Y , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^8 and
 i are each as defined in claim 1,
or a salt thereof.

20

5. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers or excipients.
- 25 6. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament.
- 30 7. A compound of claim 1 or a pharmaceutically acceptable salt thereof for use as a medicament.
- 35 8. A compound of claim 1 or a pharmaceutically acceptable salt thereof for use as selective β_3 adrenergic receptor agonists.

9. A method for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.

DATED this 30th day of December 2002

Fujisawa Pharmaceuticals Co., Ltd.

By DAVIES COLLISON CAVE
Patent Attorneys for the Applicant